BIOMAT Database Logo BIOMAT Database Logo

Six-month repeated oral toxicity study of NK-104 in rats. 1998

T Akiba, and T Shibuta, and Y Amano, and A Asanuma, and M Okubo, and K Nishigaki, and T Moriwaki, and H Yamada, and N Okamura, and T Watanabe, and T Koga, and M Tanaka, and M Takimoto
Fuji Research Laboratories Pharmaceutical Division, Kowa Company Ltd., Shizuoka, Japan.

NK-104 is a novel potent inhibitor of the rate-limiting enzyme in cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, and has been shown to be a highly effective agent in lowering blood cholesterol. In the present study, NK-104 was orally administered to Wistar rats at a dose of 0.3, 1, 3 or 010 mg/kg for 6 months for examination of toxicity. Additional recovery groups of 8 rats each of both sexes receiving 0 and 10 mg/kg were maintained without treatment for 1 month in order to assess recovery. As a result, no toxicological changes were observed in general signs, body weight, food intake, ophthalmological examination, urinalysis, hematological and blood chemical examinations for organ weights. An autopsy revealed thickening of the forestomach mucosa in both sexes at a dose of 1 mg/kg or more. This change was microscopically recognized as hyperkeratosis and hypertrophy of the spinous layer associated with both cell infiltration of the mucosal propria and edema of sub-mucosa in the forestomach in both sexes at doses of 3 and 10 mg/kg. Forestomach changes were not observed in any cases after 1 month cessation of drug treatment. The non-toxic dose of NK-104 in the 6-month repeated oral toxicity study in rats is estimated to be 1 mg/kg/day.

UI MeSH Term Description Entries
D008297 Male Males
D011804 Quinolines
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D005260 Female Females
D005753 Gastric Mucosa Lining of the STOMACH, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. The surface cells produce MUCUS that protects the stomach from attack by digestive acid and enzymes. When the epithelium invaginates into the LAMINA PROPRIA at various region of the stomach (CARDIA; GASTRIC FUNDUS; and PYLORUS), different tubular gastric glands are formed. These glands consist of cells that secrete mucus, enzymes, HYDROCHLORIC ACID, or hormones. Cardiac Glands,Gastric Glands,Pyloric Glands,Cardiac Gland,Gastric Gland,Gastric Mucosas,Gland, Cardiac,Gland, Gastric,Gland, Pyloric,Glands, Cardiac,Glands, Gastric,Glands, Pyloric,Mucosa, Gastric,Mucosas, Gastric,Pyloric Gland
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001219 Aspartate Aminotransferases Enzymes of the transferase class that catalyze the conversion of L-aspartate and 2-ketoglutarate to oxaloacetate and L-glutamate. EC 2.6.1.1. Aspartate Aminotransferase,Aspartate Transaminase,Glutamic-Oxaloacetic Transaminase,SGOT,Aspartate Apoaminotransferase,Glutamate-Aspartate Transaminase,L-Aspartate-2-Oxoglutarate Aminotransferase,Serum Glutamic-Oxaloacetic Transaminase,Aminotransferase, Aspartate,Aminotransferase, L-Aspartate-2-Oxoglutarate,Aminotransferases, Aspartate,Apoaminotransferase, Aspartate,Glutamate Aspartate Transaminase,Glutamic Oxaloacetic Transaminase,Glutamic-Oxaloacetic Transaminase, Serum,L Aspartate 2 Oxoglutarate Aminotransferase,Serum Glutamic Oxaloacetic Transaminase,Transaminase, Aspartate,Transaminase, Glutamate-Aspartate,Transaminase, Glutamic-Oxaloacetic,Transaminase, Serum Glutamic-Oxaloacetic
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats

Related Publications

T Akiba, and T Shibuta, and Y Amano, and A Asanuma, and M Okubo, and K Nishigaki, and T Moriwaki, and H Yamada, and N Okamura, and T Watanabe, and T Koga, and M Tanaka, and M Takimoto
[Toxicity study of cefmatilen hydrochloride hydrate (S-1090) (5)--Six-month repeated oral dose toxicity study and supplement study in rats].
May 2001, The Journal of toxicological sciences,
T Akiba, and T Shibuta, and Y Amano, and A Asanuma, and M Okubo, and K Nishigaki, and T Moriwaki, and H Yamada, and N Okamura, and T Watanabe, and T Koga, and M Tanaka, and M Takimoto
[Toxicity study of cefmatilen hydrochloride hydrate (S-1090) (6)--Six-month repeated oral dose toxicity study in dogs].
May 2001, The Journal of toxicological sciences,
T Akiba, and T Shibuta, and Y Amano, and A Asanuma, and M Okubo, and K Nishigaki, and T Moriwaki, and H Yamada, and N Okamura, and T Watanabe, and T Koga, and M Tanaka, and M Takimoto
[A six-month intraperitoneal repeated dose toxicity study of tazobactam/piperacillin and tazobactam in rats].
October 1994, The Journal of toxicological sciences,
T Akiba, and T Shibuta, and Y Amano, and A Asanuma, and M Okubo, and K Nishigaki, and T Moriwaki, and H Yamada, and N Okamura, and T Watanabe, and T Koga, and M Tanaka, and M Takimoto
Six-month toxicity study of oral administration of D-003 in Sprague Dawley rats.
January 2002, Drugs in R&D,
T Akiba, and T Shibuta, and Y Amano, and A Asanuma, and M Okubo, and K Nishigaki, and T Moriwaki, and H Yamada, and N Okamura, and T Watanabe, and T Koga, and M Tanaka, and M Takimoto
A one-month repeated oral dose toxicity study of methotrexate in unilaterally nephrectomized rats.
November 1998, The Journal of toxicological sciences,
T Akiba, and T Shibuta, and Y Amano, and A Asanuma, and M Okubo, and K Nishigaki, and T Moriwaki, and H Yamada, and N Okamura, and T Watanabe, and T Koga, and M Tanaka, and M Takimoto
[Six-month chronic toxicity study of miporamicin in rats].
November 1989, The Japanese journal of antibiotics,
T Akiba, and T Shibuta, and Y Amano, and A Asanuma, and M Okubo, and K Nishigaki, and T Moriwaki, and H Yamada, and N Okamura, and T Watanabe, and T Koga, and M Tanaka, and M Takimoto
Six month oral toxicity study of trinitrotoluene in beagle dogs.
August 1990, Toxicology,
T Akiba, and T Shibuta, and Y Amano, and A Asanuma, and M Okubo, and K Nishigaki, and T Moriwaki, and H Yamada, and N Okamura, and T Watanabe, and T Koga, and M Tanaka, and M Takimoto
[Toxicity studies of VP 16-213 (III)--Oral six-month chronic toxicity in rats].
April 1986, The Journal of toxicological sciences,
T Akiba, and T Shibuta, and Y Amano, and A Asanuma, and M Okubo, and K Nishigaki, and T Moriwaki, and H Yamada, and N Okamura, and T Watanabe, and T Koga, and M Tanaka, and M Takimoto
[Six-month intraperitoneal toxicity study of cefpirome sulfate in rats].
November 1990, The Journal of toxicological sciences,
T Akiba, and T Shibuta, and Y Amano, and A Asanuma, and M Okubo, and K Nishigaki, and T Moriwaki, and H Yamada, and N Okamura, and T Watanabe, and T Koga, and M Tanaka, and M Takimoto
[A six-month chronic dietary toxicity study of pyriproxyfen in rats].
February 1989, The Journal of toxicological sciences,
Copied contents to your clipboard!